Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
News
Features
Commentary
People
Events
White Papers
FEATURES
Filter By:
2012
2011
2010
2009
2008
Interest persists in new treatments for HCV
01 February 2012
Last year saw the first in a new class of product for treating hepatitis C infections reach the market. Vertex Pharmaceuticals’ Incivek (telaprevir) and Merck & Co’s Victrelis (boceprevir) are protease inhibitors (to be more accurate, they inhibit viral NS3 serine protease, an enzyme required for ...
Improved climate for clinical trials in Thailand
26 January 2012
Incoming Thai Prime Minister Yingluck Shinawatra gained much support from the local pharma community last year on announcing a series of health policy goals. She won the mandate to reform the healthcare and other sectors of the Thai economy after her PTP party’s landslide victory in the July 2011 ...
Strategies for controlling clinical study costs
05 January 2012
Clinical study design teams have historically been cost conscious, but not necessarily cost averse. The cost conscious clinical team will forecast study costs and have a keen awareness that choices made in study design will have monetary consequences for the study budget. The cost averse clinical ...
MOST MENTIONED
COMPANY/ORGANISATION
BIOLOGIC
BRISTOL-MYERS SQUIBB
DEBIOPHARM
GILEAD SCIENCES
CONDITION
HIV
ANAEMIA
ANXIETY
CANCER
GEOGRAPHY
CHINA
INDIA
INDONESIA
JAPAN
DRUG
216
BI-201335
BOCEPREVIR
CICLOSPORIN
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Partnerships in Clinical Trials
04 March 2012
The Marriott World Center, Orlando, Florida
